Identification of Linear Epitopes in Bacillus anthracis Protective Antigen Bound by Neutralizing Antibodies*

Protective antigen (PA), the binding subunit of anthrax toxin, is the major component in the current anthrax vaccine, but the fine antigenic structure of PA is not well defined. To identify linear neutralizing epitopes of PA, 145 overlapping peptides covering the entire sequence of the protein were synthesized. Six monoclonal antibodies (mAbs) and antisera from mice specific for PA were tested for their reactivity to the peptides by enzyme-linked immunosorbent assays. Three major linear immunodominant B-cell epitopes were mapped to residues Leu156 to Ser170, Val196 to Ile210, and Ser312 to Asn326 of the PA protein. Two mAbs with toxin-neutralizing activity recognized two different epitopes in close proximity to the furin cleavage site in domain 1. The three-dimensional complex structure of PA and its neutralizing mAbs 7.5G and 19D9 were modeled using the molecular docking method providing models for the interacting epitope and paratope residues. For both mAbs, LeTx neutralization was associated with interference with furin cleavage, but they differed in effectiveness depending on whether they bound on the N- or C-terminal aspect of the cleaved products. The two peptides containing these epitopes that include amino acids Leu156–Ser170 and Val196–Ile210 were immunogenic and elicited neutralizing antibody responses to PA. These results identify the first linear neutralizing epitopes of PA and show that peptides containing epitope sequences can elicit neutralizing antibody responses, a finding that could be exploited for vaccine design.

[1]  Robert C. Liddington,et al.  Crystal structure of a complex between anthrax toxin and its host cell receptor , 2004, Nature.

[2]  C. Baldari,et al.  Anthrax toxins: A paradigm of bacterial immune suppression. , 2006, Trends in immunology.

[3]  J. Zmuda,et al.  A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  L. Baillie,et al.  Characterization of the human immune response to the UK anthrax vaccine. , 2004, FEMS immunology and medical microbiology.

[5]  S. Leppla,et al.  Anthrax Protective Antigen Cleavage and Clearance from the Blood of Mice and Rats , 2007, Infection and Immunity.

[6]  B. Chait,et al.  Matrix-assisted laser desorption ionization mass-spectrometry of proteins. , 1996, Methods in enzymology.

[7]  R. Collier,et al.  Identification of residues lining the anthrax protective antigen channel. , 1998, Biochemistry.

[8]  M. Mock,et al.  Functional Analysis of Bacillus anthracis Protective Antigen by Using Neutralizing Monoclonal Antibodies , 2004, Infection and Immunity.

[9]  A. Casadevall,et al.  Capsular Localization of the Cryptococcus neoformans Polysaccharide Component Galactoxylomannan , 2008, Eukaryotic Cell.

[10]  M. Lefranc,et al.  Selection of a Macaque Fab with Framework Regions Like Those in Humans, High Affinity, and Ability To Neutralize the Protective Antigen (PA) of Bacillus anthracis by Binding to the Segment of PA between Residues 686 and 694 , 2005, Antimicrobial Agents and Chemotherapy.

[11]  R. Liddington,et al.  Crystal structure of the anthrax toxin protective antigen , 1997, Nature.

[12]  U. Moens,et al.  Human polyomavirus BK and immunogenicity of mammalian DNA: a conceptual framework. , 1997, Methods.

[13]  W. Baze,et al.  Human Monoclonal Antibody AVP-21D9 to Protective Antigen Reduces Dissemination of the Bacillus anthracis Ames Strain from the Lungs in a Rabbit Model , 2007, Infection and Immunity.

[14]  C. Corbett,et al.  Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen , 2006, FEMS immunology and medical microbiology.

[15]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[16]  D. Reed,et al.  Mapping of antibody responses to the protective antigen of Bacillus anthracis by flow cytometric analysis. , 2002, Cytometry.

[17]  K. Aktories,et al.  Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins , 2004, Microbiology and Molecular Biology Reviews.

[18]  András Fiser,et al.  Multiple mapping method: A novel approach to the sequence‐to‐structure alignment problem in comparative protein structure modeling , 2006, Proteins.

[19]  Wei Chen,et al.  The 2β2–2β3 loop of anthrax protective antigen contains a dominant neutralizing epitope , 2006 .

[20]  A. Casadevall,et al.  Monoclonal antibody based ELISAs for cryptococcal polysaccharide. , 1992, Journal of immunological methods.

[21]  D. Scheidegger,et al.  Production of monoclonal antibodies: strategy and tactics. , 1980, Journal of immunological methods.

[22]  A. Casadevall,et al.  A Monoclonal Antibody to Bacillus anthracis Protective Antigen Defines a Neutralizing Epitope in Domain 1 , 2006, Infection and Immunity.

[23]  M. Sternberg,et al.  Modelling protein docking using shape complementarity, electrostatics and biochemical information. , 1997, Journal of molecular biology.

[24]  M. J. Rosovitz,et al.  Alanine-scanning Mutations in Domain 4 of Anthrax Toxin Protective Antigen Reveal Residues Important for Binding to the Cellular Receptor and to a Neutralizing Monoclonal Antibody* , 2003, Journal of Biological Chemistry.

[25]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[26]  R. Titball,et al.  A Recombinant Carboxy-Terminal Domain of the Protective Antigen of Bacillus anthracis Protects Mice against Anthrax Infection , 2002, Infection and Immunity.

[27]  Jerome Hauer,et al.  Anthrax as a biological weapon, 2002: updated recommendations for management. , 2002, JAMA.

[28]  PA63 Channel of Anthrax Toxin: An Extended β-Barrel† , 2002 .

[29]  A. Casadevall,et al.  Immunogenicity of Bacillus anthracis Protective Antigen Domains and Efficacy of Elicited Antibody Responses Depend on Host Genetic Background , 2008, Clinical and Vaccine Immunology.